Ciclesonide and the treatment of asthma

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 3, 2010, Pages 463-479

  Korenblat, Phillip E ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Asthma; Ciclesonide; Delivery; Efficacy; Inhaled corticosteroids; Pharmacodynamics; Pharmacokinetics; Quality of life; Safety; Systemic effects

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOMETASONE FUROATE; NEDOCROMIL; PLACEBO; SALBUTAMOL; TETRACOSACTIDE; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; ZILEUTON;

ADRENAL SUPPRESSION; ASTHMA; CATARACTOGENESIS; CIRCADIAN RHYTHM; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; ENDOCRINE FUNCTION; FORCED EXPIRATORY VOLUME; GROWTH RATE; HOARSENESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; LUNG FUNCTION; METERED DOSE INHALER; MORNING DOSAGE; PEAK EXPIRATORY FLOW; PHARYNGITIS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SIDE EFFECT; THRUSH;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LUNG; PHARYNGEAL DISEASES; PITUITARY-ADRENAL SYSTEM; PRACTICE GUIDELINES AS TOPIC; PREGNENEDIONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 76449116090     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903575647     Document Type: Review

References (93)

1. GINA-the global initiative for asthma. Global strategy for asthma management and prevention. 2008 revised. Available from: http://www.ginasthma. com/
2. National Center for Health Statistics. Asthma prevalence, health care use and mortality: United States, 2003-2005. 2009; Available from: http://www.cdc.gov.nchs/ products/pubs/pubd/hestats/asthma03-05/ asthma03-05.htm
3. Redd SC. Asthma in the United States: burden and current theories. Environ Health Perspect 2002;110(Suppl 4):557-560
4. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol 2009;71:489-507
5. Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy 2009;39(11):1652-1658
6. Folli C, Descalzi D, Scordamaglia F, et al. New insights into airway remodelling in asthma and its possible modulation. Curr Opin Allergy Clin Immunol 2008;8(5):367-375
7. NHLBI and National Asthma Education and Prevention Program Coordinating Committee Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Available from: http://www.nhlbi.gov/guidelines/asthma/ asthgdln.pdf
8. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26
9. Adams RJ, Fuhlbrigge A, Guilbert T, et al. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol 2002;110(1):58-64
10. Milgrom H, Bender B, Ackerson L, et al. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98(6 Pt 1):1051-1057
11. Canonica GW, Baena-Cagnani CE, Blaiss MS, et al. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: global adult findings. Allergy 2007;62(6):668-674
12. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998;113(3):587-592
13. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112(3 Suppl):S1-40
14. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157(3 Pt 2):S1-53 (Pubitemid 28125600)
15. Humbert M. The right tools at the right time. Chest 2006;130(1 Suppl):29S-40S
16. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/ pharmacodynamic perspective. J Clin Pharmacol 2004;44(1):37-47
17. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002;87(5):2160-2163
18. Alvesco package insert. Available at: http://www.alvesco.us/AlvescoPI.pdf
19. Dietzel K, Engelstaetter R, Keller A. Ciclesonide: an on-site activated steroid. 2001;31:91-93
20. Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28(5):1042-1050
21. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 2007;73(10):1657-1664
22. Craig T. The safety profile of ciclesonide in the treatment of persistent asthma. Allergy Asthma Proc 2009;30(3):315-324
23. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005;61(3):203-208
24. Newman S, Salmon A, Nave R, et al. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006;100(3):375-384
25. Peet CF, Enos T, Nave R, et al. Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet 2005;30(4):275-286
26. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005;12(3):201-209
27. Drollmann A, Nave R, Steiner I. Negligible concentration of unbound des-CIC in muscle and subcutaneous adipose tissue after inhalation of ciclesonide in a supra-therapeutic dose. Proc Am Thorac Soc 2006;3(Suppl):A75
28. Leach CL, Bethke TD, Boudreau RJ, et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med 2006;19(2):117-126
29. Colice GL. The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma. Expert Opin Pharmacother 2006;7(15):2107-2117
30. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005;45(2):146-152
31. Berger WE, Kerwin E, Bernstein DI, et al. Efficacy and safety evaluation of ciclesonide in subjects with mild-to-moderate asthma not currently using inhaled corticosteroids. Allergy Asthma Proc 2009;30(3):304-314
32. Pearlman DS, Berger WE, Kerwin E, et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 2005;116(6):1206-1212
33. Bateman ED, Linnhof AE, Homik L, et al. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008;21(2):264-275
34. Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 2005;99(10):1275-1285
35. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005;60(3):330-337
36. Korenblat P, Weinstein S, Noonan M, et al. Ciclesonide 80g twice daily or 160g once daily AM significantly maintained lung function compared with placebo in patients with asthma who have previously received an inhaled corticosteroid. Ann Allergy Asthma Immunol 2009;102(Suppl 1):A44
37. Weinstein S, Meltzer E, LaForce C, et al. Ciclesonide 80g twice daily or 160g once daily AM maintains variables of asthma contgrol in adults with stable mild-to-moderate asthma previously treated with an inhaled corticosteroid. Ann Allergy Asthma Immunol 2009;102(Suppl 1):A45
38. Meltzer EO, Korenblat PE, Weinstein SF, et al. Efficacy and safety evaluation of ciclesonide in mild-to-moderate persistent asthma previously treated with inhaled corticosteroids. Allergy Asthma Proc 2009;30(3):293-303
39. Bateman E, Karpel J, Casale T, et al. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006;129(5):1176-1187
40. Gelfand EW, Georgitis JW, Noonan M, et al. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr 2006;148(3):377-383
41. Pedersen S, Garcia Garcia ML, Manjra A, et al. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 2006;41(10):954-961
42. Skoner DP, Maspero J, Banerji D. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 2008;121(1):e1-14
43. Sepracor, Securities and Exchange Commission Filings. Available from: http://phx.corporate-ir.net/phoenix.zhtml? c=90106&p = irol-sec& secCat01.1-rs=51&secCat01.1-rc=10.
44. Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 2006;19(6):404-412
45. Boulet LP, Bateman ED, Voves R, et al. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med 2007;101(8):1677-1686
46. Busse W, Kaliner MA, Berstein D. The novel inhaled corticosteroid ciclesonide is efficacious and has a favourable safety profile in adults and adolescents with severe persistent asthma. J Allergy Asthma Immunol 2005;115(2):S213
47. Ukena D, Biberger C, Steinijans V, et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther 2007;20(5):562-570
48. Boulet LP, Drollmann A, Magyar P, et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 2006;100(5):785-794
49. Hansel TT, Benezet O, Kafe H, et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther 2006;28(6):906-920
50. Adachi M, Ishihara K, Inoue H, et al. Efficacy and safety of inhaled ciclesonide compared with chlorofluorocarbon beclomethasone dipropionate in adults with moderate to severe persistent asthma. Respirology 2007;12(4):573-580 (Pubitemid 46961837)
51. Jenkins CR, Thien FC, Wheatley JR, et al. Traditional and patient-centred outcomes with three classes of asthma medication. Eur Respir J 2005;26(1):36-44
52. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;99(2):S742-9
53. Kauppinen R, Sintonen H, Vilkka V, et al. Quality-of-life measures and clinical parameters in asthmatics during three year follow-up. Monaldi Arch Chest Dis 1998;53(4):400-404
54. Nathan RA, Kanter L, Ostrom NK. Ciclesonide improves health-related quality of life in adults and adolescents with mild-to-moderate persistent asthma. Allergy Asthma Proc 2008;29(5):521-527
55. Bernstein DI, Nathan RA, Ledford D. Ciclesonide, a new inhaled corticosteroid, significantly improves asthma-related quality of life in patients with severe, persistent asthma. J Allergy Clin Immunol 2005;115(2):S210
56. Miller D, Ratner P, Condemi J. Once-daily ciclesonide improves quality of life in pediatric patients with asthma. J Allergy Clin Immunol 2005;115(2):S211
57. Magnussen H, Hofman J, Staneta P, et al. Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma. J Asthma 2007;44(7):555-563
58. Niphadkar P, Jagannath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther 2005;27(11):1752-1763
59. Chylack LT Jr, Gross GN, Pedinoff A. A randomized, controlled trial to investigate the effect of ciclesonide and beclomethasone dipropionate on eye lens opacity. J Asthma 2008;45(10):893-902
60. Banerji D, Szwareberg J, Fish J. The incidence of oropharyngeal adverse events in adolsecent/adults and pediatric asthma patients is similar for ciclesonide and placebo: results from pooled analyses. Allergy Asthma Proc 2004;25(3):P206
61. Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 2005;115(5):940-945
62. Meltzer EO, Sotomayor J, Kundu S, et al. Long-term safety profile of once-daily ciclesonide in children with persistent asthma of all severities. Ann Allergy Asthma Immunol 2006;96(1):140-141
63. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006;61(5):518-526
64. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004;126(1):213-219
65. Kaliner M, Amin A, Gehling R. Impact of inhaled corticosteroid-induced oropharyngeal adverse effects on treatment patterns and costs in asthmatic patients: results from a Delphi Panel. Pharmacy & Therapeutics 2005;30(10):573-601
66. Postma DS, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001;17(6):1083-1088
67. Berger W, Galant S, Kundu S, et al. Long-term safety profile of once-daily ciclesonide in adults/adolescents with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2006;96(4):140
68. Korenblat P, Bernstein D, Fish J. Ciclesonide HFA-MDI has a lower incidence or oral candidiasis than beclomethasone dipropionate HFA-MDI in patients with severe persistent asthma: results of a long-term study. Ann Allergy Asthma Immunol 2005;94(1):173
69. Engelstaetter R, Banerji D, Steinijans V, et al. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide: results from a pooled analysis. Am J Respir Crit Care Med 2004;169(7):A72
70. Leske MC, Wu SY, Nemesure B, et al. Risk factors for incident nuclear opacities. Ophthalmology 2002;109(7):1303-1308
71. Leske MC, Chylack LT Jr, He Q, et al. Incidence and progression of cortical and posterior subcapsular opacities: the Longitudinal Study of Cataract. The LSC Group. Ophthalmology 1997;104(12):1987-1993
72. Leske MC, Chylack LT Jr, He Q, et al. Risk factors for nuclear opalescence in a longitudinal study. LSC Group. Longitudinal Study of Cataract. Am J Epidemiol 1998;147(1):36-41
73. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003;112(3):469-478
74. Berger WE. Ciclesonide: a closer look at its systemic and oropharyngeal safety profile. Curr Drug Saf 2006;1(3):265-270
75. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005;94(4):465-472
76. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18(5):328-336
77. Nave R, Bethke TD, van Marle SP, et al. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 2004;43(7):479-486
78. Nave R, Bethke T, Seiberling M. Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects. Eur Respir J 2002;20(Suppl 38):749
79. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol 2007;47(6):782-789
80. Schleimer RP, Kato A, Kern R, et al. Epithelium: at the interface of innate and adaptive immune responses. J Allergy Clin Immunol 2007;120(6):1279-1284
81. Adachi M, Ishihara K, Inoue H, et al. Efficacy and safety of once-daily inhaled ciclesonide in adults with mild to moderate asthma: a double-blind, placebo-controlled study. Respirology 2007;12(4):566-572 (Pubitemid 46961836)
82. Eggleston PA. Complex interactions of pollutant and allergen exposures and their impact on people with asthma. Pediatrics 2009;123(Suppl 3):S160-S167
83. Maziak W. Endotoxin and asthma. N Engl J Med 2003;348(2):171-174
84. Kearley J, Robinson DS, Lloyd CM. CD4 +CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J Allergy Clin Immunol 2008;122(3):617-624
85. Ebner S, Nguyen VA, Forstner M, et al. Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J Allergy Clin Immunol 2007;119(4):982-990
86. Edwards MR, Bartlett NW, Clarke D, et al. Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009;121(1):1-13
87. Kim EY, Battaile JT, Patel AC, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 2008;14(6):633-640
88. Circassia Limited and Adiga Life Sciences. Safety of toleromune ragweed to treat ragweed allergy in ragweed allergic subjects with rhiniconjunctivitis. Available from: http://clinicaltrials.gov/ct2/show? NCT00878774. [Last accessed October 2009]
89. Kumar A, Ghosh B. Genetics of asthma: a molecular biologist perspective. Clin Mol Allergy 2009;7:7
90. Heijink IH, Kauffman HF, Vellenga E, et al. Effect of ciclesonide treatment on allergen-induced changes in T cell regulation in asthma. Int Arch Allergy Immunol 2008;145(2):111-121
91. Kawayama T, O'Byrne PM, Watson RM, et al. Effects of inhaled ciclesonide on circulating T-helper type 1/T-helper type 2 cells in atopic asthmatics after allergen challenge. Clin Exp Allergy 2006;36(11):1417-1424
92. Szefler S, Rohatagi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005;128(3):1104-1114
93. Sato H, Nave R, Nonaka T, et al. Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa. BMC Pharmacol 2007;7(7):1-8